Organ transplant immunosuppressant drugs are used to reduce rejection in organ transplantation procedures such as kidney, heart, liver and other organs. These drugs help prevent the immune system from attacking and rejecting the transplanted organ by suppressing or lowering the body’s immune system response. Common classes of drugs used include calcineurin inhibitors, antiproliferative agents, corticosteroids and others. With rising cases of organ failure worldwide and lack of organ donors, the demand for organ transplant procedures is growing rapidly thereby driving the immunosuppressant drugs market.
The Organ Transplant Immunosuppressant Drugs Market is estimated to be valued at US$ 5.17 Bn in 2023 and is expected to exhibit a CAGR of 3.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The organ transplant immunosuppressant drugs market is primarily driven by growing prevalence of chronic diseases leading to organ failure and shortage of organ donors around the world. According to WHO, currently more than 1.5 million people worldwide are added to waiting lists for organ transplantation every year while only around 100,000 transplants are performed annually. The shortage of organ donors leads to increasing backlog of patients waiting for transplantation and delayed wait times for organs. This is increasing demand for immunosuppressant therapy post-transplantation. Additionally, developments in pharmacological sciences resulting in more effective and less toxic drugs for immunosuppression is also propelling market growth over the forecast period. However, high costs associated with organ transplantation surgery and lifelong immunosuppressive drug therapy along with possible side effects of these drugs limits market prospects to some extent.
Segment Analysis
The organ transplant immunosuppressant drugs market is segmented based on the transplantation type into kidney transplantation, liver transplantation, heart transplantation, lung transplantation, and other organ transplantations. The kidney transplantation segment dominated the market in 2023 due to the increasing prevalence of chronic kidney disease and growing number of organ donors.
PEST Analysis
Political: The market is positively impacted by various government initiatives and funding for research activities related to organ transplantation. However, stringent regulations may hamper the market growth.
Economic: The rising healthcare spending and increasing income levels are the key factors driving the demand for organ transplantation and immunosuppressant drugs globally.
Social: Growing organ donation awareness programs and increasing living organ donations are supporting the market growth.
Technological: Advancements in transplant techniques, development of novel biologics, and combination therapies are expected to present lucrative opportunities for market players.
Key Takeaways
The Global Organ Transplant Immunosuppressant Drugs Market Size is expected to witness high growth, exhibiting CAGR of 3.1% over the forecast period, due to increasing prevalence of organ failure across the globe. The market size for 2023 is estimated to be US$ 5.17 Bn.
Regional analysis: North America dominates the global market and is expected to maintain its lead over the forecast period owing to the rising incidence of end-stage organ failure, availability of reimbursement, and increasing number of organ transplants in the region.
Key players: Key players operating in the organ transplant immunosuppressant drugs market are Astellas Pharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline plc., Belcher Pharmaceuticals LLC, Leo Pharma As, Glenmark Pharmaceuticals Ltd., TFF Pharmaceuticals, Inc., TolerogenixX GmbH, Veloxis Pharmaceuticals Inc., Dr. Reddys Laboratories Ltd., Panacea Biotec Ltd., Strides Pharma Global Pte Ltd., and Hoffman La Roche.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it